Intellicell Biosciences Inc (fka SVFC)

[Y_Razz]

Licensing agreements made as per date:

1) Stem Cells 21 of Thailand: The Thailand Agreement shall have an initial term ending on April 7, 2022, and shall continue on successive one-year terms thereafter unless terminated by either party (the “Term”).

In addition to the foregoing, for each tissue processing case performed by Thailand Licensee, a fee of twelve and one-half percent (12.5%) of the fess designated by the Company for tissue processing shall be remitted to the Company on a monthly basis. Thailand Licensee shall also pay the Company a fee of twelve and one-half percent (12.5%) of the all profit earned by the Thailand Licensee form the initial up front sale of lab equipment to other laboratory facilities who acquire a sublicense from the Thailand Licensee to use the Technology in the Territory.

http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=8541622-1217-10519&type=sect&TabIndex=2&companyid=80700&ppu=%252fdefault.aspx%253fcik%253d1125280

(http://www.stemcells21.com/) (http://www.intellihealthplus.com/)

2) RegenaStem in Canada (operating as IntelliCell
BioSciences of Canada) for $500,000 upfront and a 30% share of
revenues.

3) Licensed by Cell-Innovations, Pty Limited in Australia for $700,000
upfront and a 12.5% share of revenues.

4) Effective March 7, 2014, with The Andrews Research and Education Foundation, Inc. shall pay to the Company a fee equal to Two Thousand Five Hundred Dollars ($2,500.00) per Tissue Processing (as such term is defined in the License Agreement) case processed.

Have I missed any other licensing agreements? :)

Basically for centers of excellence, such as the andrews institute, we are taking 2.5% per tissue. For licensing with other clinics we are taking upfront payments and between 12.5%-30% revenues.


According to Bioinformant Worldwide LLC, "There is conclusive evidence that entering the stem cell research products market is fiscally worthwhile. Full-year 2011 analysis determines the size the stem cell research products market to be $2.59 billion, and the stem cell therapies market to be $3.13 billion, for a total of $5.72 billion. In addition, both markets are growing with double-digit growth. Producing stem cell research products thus represents a massive profit opportunity for research supply companies."

Dr. Victor said, "The future of medicine will reach an exciting stage when SVF will be stored in all major hospitals, similar to blood for transfusions, and these cells will be readily available to treat patients for a multitude of injuries and ailments (ie. orthopaedic, post myocardial infarction etc.). We believe this discovery will change the way patients are treated."